Trials / Not Yet Recruiting
Not Yet RecruitingNCT06975475
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by Trastuzumab，pyrotinib and Nab-Paclitaxel in second line for HER2 positive breast cancer brain metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel | SHR-A1811:4.8mg/kg tratuzumab:Initial 8mg/kg followed by 6mg/kg pyrotinib:320mg Nab-Paclitaxel:100-150mg/m2 |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
- First posted
- 2025-05-16
- Last updated
- 2025-05-16
Source: ClinicalTrials.gov record NCT06975475. Inclusion in this directory is not an endorsement.